MEI Pharma Inc (LTS:0JW9)
$ 3.102 -0.0388 (-1.24%) Market Cap: 21.05 Mil Enterprise Value: -17.29 Mil PE Ratio: 1.16 PB Ratio: 0.62 GF Score: 54/100

MEI Pharma Inc Zandelisib Phase 2 TIDAL Study Data Webcast Transcript

Nov 30, 2021 / 01:00PM GMT
Release Date Price: $64.4 (+5.98%)
Operator

Good morning, and welcome to the MEI Pharma Phase II TIDAL Study Data Announcement Webcast. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference over to David Walsey, Senior Vice President. Please go ahead.

David A. Walsey
MEI Pharma, Inc. - SVP of Corporate Affairs

Thank you, Andrea. Thank you. On our video webcast today, we will review data from the Phase II TIDAL study evaluating our investigational drug candidate, zandelisib, announced earlier today. We will also review additional data and information related to the zandelisib program.

Before we get started, I want to call your attention to the fact that this conference call may contain certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in our forward-looking statements, which are based on management's current expectations and are subject to a number of risks and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot